GALT - ガレクチン・セラピュ―ティクス （Galectin Therapeutics Inc.）

Gainers: Kiora Pharmaceuticals KPRX +39%.Celyad Oncology CYAD +35%.Oak Street Health OSH +30%.Zhihu (ZH) +27%.Berkshire Grey (BGRY) +27%.Galectin Therapeutics (GALT) +19%.Golden…

Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of esophago-gastric endoscopies when evaluating candidate therapies for liver cirrhosis. Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of esophago-gastric endoscopies when evaluating candidate therapies for liver cirrhosis.

Galectin Therapeutics is all-in on the results of one clinical trial coming in 2024. Click here to read my analysis of GALT stock.

The following slide deck was published by Galectin Therapeutics Inc.

Galectin Therapeutics press release (GALT): Q3 GAAP EPS of -$0.14.The company believes it has sufficient cash of $15.8M, including availability under its $60 million line of credit,…

Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of esophago-gastric endoscopies when evaluating candidate therapies for liver cirrhosis. Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of esophago-gastric endoscopies when evaluating candidate therapies for liver cirrhosis.

Galectin Therapeutics is all-in on the results of one clinical trial coming in 2024. Click here to read my analysis of GALT stock.

The following slide deck was published by Galectin Therapeutics Inc.

Galectin Therapeutics press release (GALT): Q3 GAAP EPS of -$0.14.The company believes it has sufficient cash of $15.8M, including availability under its $60 million line of credit,…

NORCROSS, Ga., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results a…

Galectin Therapeutics (GALT) said on Wednesday it had filed an investigational New Drug application with the U.S

NORCROSS, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12-14, 2022. The Wainwright Conference brings together thought leaders and practitioners from numerous fields to participate in presentations, one-on-one investor meetings, and networking opportunities with other attendees.

Galectin Therapeutics press release (GALT): Q2 GAAP EPS of -$0.16.As of June 30, 2022, the Company had $24.2M of cash and cash equivalents

NORCROSS, Ga., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2022. These results are included in the Company''s Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov .

Gainers Athersys, Inc. (NASDAQ: ATHX ) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 2022. SKYX Platforms Corp. (NASDAQ: SKYX ) gained 68.6% to settle at $7.03. Benchmark initiated coverage on SKYX Platforms with a Buy rating and announced a price target of $15. ECB Bancorp, Inc. (NASDAQ: ECBK ) jumped 40.9% to close at $14.09. Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS ) climbed 37.1% to close at $1.92. Q&K International Group Limited (NASDAQ: QK ) gained 32.6% to close at $1.87. JAKKS Pacific, Inc. (NASDAQ: JAKK ) shares surged 31.5% to close at $22.46 after the company reported better-than-expected Q2 results. Better Therapeutics, Inc. (NASDAQ: BTTX ) surged 30.9% to close at $1.99 after the company completed its clinical trial for BT-001, an investigational prescription digital therapeutic that is designed to use nCBT to treat type 2 diabetes. Sunrun Inc. (NASDAQ: RUN ) surged 30% to settle at $30.92 alongside Sunnova Energy International after the company reported strong top-line financial results and reaffirmed guidance.